<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180544</url>
  </required_header>
  <id_info>
    <org_study_id>99-707</org_study_id>
    <nct_id>NCT00180544</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease</brief_title>
  <acronym>HERCULINK 14</acronym>
  <official_title>A Prospective, Non-Randomized, Multicenter, Single-Arm, Clinical Trial to Assess the Safety and Efficacy of the RX HERCULINK 14 Peripheral Stent System for Treatment in de Novo or Restenotic Renal Artery Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the RX HERCULINK 14
      Peripheral Stent System in treating atherosclerotic renal artery stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, non-randomized, multi-center, single-arm clinical trial to evaluate the safety
      and efficacy of the RX HERCULINK™ 14 Peripheral Stent System in the treatment of suboptimal
      post- procedural percutaneous transluminal angioplasty (PTA) results in de novo or restenotic
      atherosclerotic renal artery stenoses.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Device superceded by next generation device. Enrollment stopped, long term follow up was
    completed in August of 2004.
  </why_stopped>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency .</measure>
    <time_frame>at 9-months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success</measure>
    <time_frame>Acute</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access site events requiring surgical repair or intervention</measure>
    <time_frame>Acute</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events (e.g. death, nephrectomy, target lesion revascularization (TLR)</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLR</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>measured at 1, 6, 9, and 12-month follow-up, and every three months thereafter until approximately May 2003 or until patient 169 completes 12 month follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Renal Artery Obstruction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stenting: Renal Artery</intervention_name>
    <description>Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of renal artery atherosclerosis; candidate for renal artery
             angioplasty and stenting; blood pressure &gt;160/90

        Exclusion Criteria:

          -  Totally occluded renal artery on the opposite side; only one functioning kidney;
             target lesion is in a transplanted kidney; renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ramee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alton Ochsner Medical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alton Ochsner Medical Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>July 24, 2008</last_update_submitted>
  <last_update_submitted_qc>July 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Maureen Kennedy</name_title>
    <organization>Abbott Vascular</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

